Metabolites extracted from microorganisms as potential inhibitors of glycosidases (α-glucosidase and α-amylase): A review

被引:14
作者
Wang, Xiaojing [1 ,2 ,3 ]
Li, Jiaying [2 ,4 ]
Shang, Jiaqi [2 ,5 ]
Bai, Jing [6 ]
Wu, Kai [2 ,3 ]
Liu, Jing [2 ,7 ]
Yang, Zhijun [2 ,3 ]
Ou, Hao [8 ]
Shao, Lei [2 ,3 ]
机构
[1] Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, Shanghai, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Microbial Pharmacol Lab, Shanghai, Peoples R China
[3] Shanghai Univ Med & Hlth Sci, Sch Pharm, Shanghai, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China
[5] Univ Shanghai Sci & Technol, Sch Med Instrument & Food Engn, Shanghai, Peoples R China
[6] Suzhou Univ Sci & Technol, Sch Chem & Life Sci, Suzhou, Peoples R China
[7] Shanghai Univ Med & Hlth Sci, Sch Med Technol, Shanghai, Peoples R China
[8] Cent South Univ, Xiangya Hosp 3, Dept Crit Care Med, Changsha, Hunan, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
alpha-glucosidase inhibitor; alpha-amylase inhibitor; microbes; endophytes; marine microorganism; medical application; SECONDARY METABOLITES; BIOLOGICAL-ACTIVITIES; FUNGUS; 1-DEOXYNOJIRIMYCIN; COMBINATION; VALIOLAMINE; VOGLIBOSE; SPECTRUM; ACARBOSE; MODEL;
D O I
10.3389/fmicb.2022.1050869
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
alpha-Glucosidase and alpha-amylase are the two main glycosidases that participate in the metabolism of carbohydrates. Inhibitors of these two enzymes are considered an important medical treatment for carbohydrate uptake disorders, such as diabetes and obesity. Microbes are an important source of constituents that have the potential to inhibit glycosidases and can be used as sources of new drugs and dietary supplements. For example, the alpha-glucosidase inhibitor acarbose, isolated from Actinoplanes sp., has played an important role in adequately controlling type 2 diabetes, but this class of marketed drugs has many drawbacks, such as poor compliance with treatment and expense. This demonstrates the need for new microorganism-derived resources, as well as novel classes of drugs with better compliance, socioeconomic benefits, and safety. This review introduces the literature on microbial sources of alpha-glucosidase and alpha-amylase inhibitors, with a focus on endophytes and marine microorganisms, over the most recent 5 years. This paper also reviews the application of glycosidase inhibitors as drugs and dietary supplements. These studies will contribute to the future development of new microorganism-derived glycosidase inhibitors.
引用
收藏
页数:13
相关论文
共 116 条
[1]   Investigating on the Correlation Between Some Biological Activities of Marine Sponge-Associated Bacteria Extracts and Isolated Diketopiperazines [J].
Abd El-Hady, Faten K. ;
Fayad, Walid ;
Iodice, Carmine ;
El-Shahid, Zeinab A. ;
Abdel-Aziz, Mohamed S. ;
Crudele, Egle ;
Tommonaro, Giuseppina .
CURRENT MICROBIOLOGY, 2017, 74 (01) :6-13
[2]   Antidiabetic xanthones with α-glucosidase inhibitory activities from an endophytic Penicillium canescens [J].
Abd Malik ;
Ardalani, Hamidreza ;
Anam, Syariful ;
McNair, Laura Mikel ;
Kromphardt, Kresten J. K. ;
Frandsen, Rasmus John Normand ;
Franzyk, Henrik ;
Staerk, Dan ;
Kongstad, Kenneth T. .
FITOTERAPIA, 2020, 142
[3]   The antidiabetic potential of endophytic fungi: Future prospects as therapeutic agents [J].
Agrawal, Shivankar ;
Samanta, Sreeparna ;
Deshmukh, Sunil Kumar .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2022, 69 (03) :1159-1165
[4]   In Vitro Anti-diabetic Activities and Chemical Analysis of Polypeptide-k and Oil Isolated from Seeds of Momordica charantia (Bitter Gourd) [J].
Ahmad, Zuraini ;
Zamhuri, Khairul Faizi ;
Yaacob, Azhar ;
Siong, Chiong Hoe ;
Selvarajah, Malarvili ;
Ismail, Amin ;
Hakim, Muhammad Nazrul .
MOLECULES, 2012, 17 (08) :9631-9640
[5]  
Akmal M., 2022, STAT PEARLS INTERNET
[6]  
Alcantara M., 2019, THESIS, V27, P631
[7]   Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs [J].
Artasensi, Angelica ;
Pedretti, Alessandro ;
Vistoli, Giulio ;
Fumagalli, Laura .
MOLECULES, 2020, 25 (08)
[8]   Glycosidase inhibitors: update and perspectives on practical use [J].
Asano, N .
GLYCOBIOLOGY, 2003, 13 (10) :93R-104R
[9]  
Baron AD, 1998, DIABETES RES CLIN PR, V40, pS51
[10]  
Bilal Shah S., 2018, MOJ Bioequivalence & Bioavailability, V5, P270, DOI [10.15406/mojbb.2018.05.00113, DOI 10.15406/MOJBB.2018.05.00113]